ERBB2 and neoplasm: Throughout the experiment, the mice treated with sCAR-T cells and HER2-specific switches remained tumor-free, as did mice treated with conventional HER2 CAR-T, demonstrating that the sCAR platform is promising against aggressive and diffuse tumors derived from patients with advanced PDAC (21).